Gallium Ga 68-DOTA-TOC PET/CT or PET/MRI in Imaging Patients with Somatostatin Receptor Positive Tumors

Inclusion Criteria

• Known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; pheochromocytoma; supporting evidence may include MRI, CT, biochemical markers, and or pathology report
• Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
• Not pregnant; a negative serum pregnancy test is required for all female subjects with child-bearing potential
• Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria

• Hepatic enzymes 5 times greater than the upper limits of normal
• Serum creatinine > 3.0 mg/dL (270 uM/L)
• Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET/CT scanner due to body mass index (BMI)
• Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.); although at Mission Bay Hospital pediatric patients may be sedated per clinical protocol
• Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
• Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
• Recognized concurrent active infection
• Previous systemic or radiation treatment for another cancer of any type within the last 2 months
• Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments